Cardiac hypertrophy in chronic kidney disease—role of Aldosterone and FGF23

Table 1 Aldosterone blockers for LV hypertrophy in CKD

	Authors	Study duration	LV mass index	LV function	Hyperkalemia vs placebo	Ref
CKD
DM nephropathy	Sato A. et al.	24 weeks	Decreased		(No change)	[10]
Stage 2~3 CKD	Edwards NC et al.	40 weeks	Decreased	Improved	No difference	[45, 46]
Hemodialysis
	Feniman-De-Ste fano GM et al.	6 months	Decreased	No change	No difference	[47]
	Taheri S et al.	6 months	Decreased	Improved	No difference	[48]
	Lin C. et al.	2 years	Decreased	Improved	No difference	[49]
	Matsumoto Y et al.	3 years	Reduced death from cardiovascular events		3 of 157 patients discontinued	[53]
Peritoneal dialysis
	Ito Y. et al.	2 years	Decreased	Improved	No difference	[50]
	Taheri S. et al.	6 months		Improved	No difference	[51]
	Hausmann MJ et al.	10 months		Improved	(No change)	[52]

ISSN: 2059-1381